Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.
A large body of evidence supports the hypothesis that mesolimbic dopamine (DA) mediates, in animal models, the reinforcing effects of central nervous system stimulants such as cocaine and amphetamine. The role DA plays in mediating amphetamine-type subjective effects of stimulants in humans remains to be established. Both amphetamine and cocaine increase norepinephrine (NE) via stimulation of release and inhibition of reuptake, respectively. If increases in NE mediate amphetamine-type subjective effects of stimulants in humans, then one would predict that stimulant medications that produce amphetamine-type subjective effects in humans should share the ability to increase NE. To test this hypothesis, we determined, using in vitro methods, the neurochemical mechanism of action of amphetamine, 3,4-methylenedioxymethamphetamine (MDMA), (+)-methamphetamine, ephedrine, phentermine, and aminorex. As expected, their rank order of potency for DA release was similar to their rank order of potency in published self-administration studies. Interestingly, the results demonstrated that the most potent effect of these stimulants is to release NE. Importantly, the oral dose of these stimulants, which produce amphetamine-type subjective effects in humans, correlated with the their potency in releasing NE, not DA, and did not decrease plasma prolactin, an effect mediated by DA release. These results suggest that NE may contribute to the amphetamine-type subjective effects of stimulants in humans.
Rothman
R B
RB
Clinical Psychopharmacology Section, Intramural Research Program, NIDA, NIH, Baltimore, Maryland 21224, USA. RROTHMAN@INTRA.NIDA.NIH.GOV
Baumann
M H
MH
Dersch
C M
CM
Romero
D V
DV
Rice
K C
KC
Carroll
F I
FI
Partilla
J S
JS
D000661:Amphetamine / Q000819:agonists*; D000818:Animals; D002352:Carrier Proteins / Q000187:drug effects / Q000378:metabolism; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D009434:Neural Pathways / Q000187:drug effects* / Q000378:metabolism; D014179:Neurotransmitter Uptake Inhibitors / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism* / Q000493:pharmacokinetics; D051381:Rats; D012701:Serotonin / Q000378:metabolism* / Q000493:pharmacokinetics; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism; D014316:Tritium
D002352:Carrier Proteins; D000697:Central Nervous System Stimulants; D014179:Neurotransmitter Uptake Inhibitors; D014316:Tritium; D012701:Serotonin; D000661:Amphetamine; D004298:Dopamine; D009638:Norepinephrine